Solara Active Pharma Sciences Share Price Today

Solara Active Pharma to host analyst call on Oct 16 for Q2FY27 results

Solara Active Pharma Sciences scheduled an analyst call for October 16, 2026. The meeting will cover unaudited financial results for Q2FY27 and H1FY27. Conference call is set for 4:00 pm IST with participation from MD & CEO and CFO. Dial-in details provided for investors and analysts joining the group meet.

Solara Pharma approves forfeiture notice for unpaid rights shares

Solara Active Pharma Sciences approved a final reminder-cum-forfeiture notice on October 9, 2026. The notice applies to holders of partly paid-up rights shares with unpaid call money. Outstanding amounts include both first and second/final call money. The company will intimate stock exchanges upon dispatch of the final notice.

Solara Active Pharma declares AGM voting results; all resolutions pass

All five resolutions at Solara Active Pharma's Ninth AGM passed with requisite majority. ₹480 crore related-party transaction with Strides Pharma approved by 99.87% of valid votes. Promoters abstained from voting on the related-party deal due to interest in the agenda. Voting results disclosed under Regulation 44 of SEBI Listing Regulations.

Solara Active Pharma gets ₹161.92 crore tax demand dropped for AY 2019-20

Solara Active Pharma Sciences received a rectification order dropping a ₹161.92 crore tax demand. The dispute related to Assessment Year 2019-20 and was resolved by the Thane income tax authority. The company confirmed there is no financial or operational impact from this development. No penalties or sanctions were imposed as part of the resolution.

Solara Active Pharma files FY26 sustainability report with 81% renewable energy mix

Renewable energy constituted 81% of total energy consumption in FY26. Permanent employee turnover rate fell to 13% from 30% in FY25. Sales to related parties rose to 25% of total sales from 17.6%. Scope 1 and 2 GHG emission intensity declined to 0.0000027 tCO₂e/₹. Total water withdrawal increased to 3,81,529 KL from 3,17,477 KL.

Solara Active Pharma Sciences FY26 Results: Revenue up 7% to ₹1,375.14 crore, net loss widens

Solara Active Pharma Sciences reported consolidated revenue of ₹1,375.14 crores in FY2025-26, up 7% YoY, while net loss widened to ₹7.41 crores from a profit of ₹0.54 crores in FY25. Consolidated EBITDA declined 10% to ₹191.54 crores; EBITDA margin contracted to 13.9% from 16.5%. Base API business revenue grew 6% to ₹1,041.40 crores with stable EBITDA of ₹244.50 crores; Ibuprofen EBITDA deteriorated to ₹(52.96) crores, down 76%. Net debt reduced to ₹614 crores from ₹772 crores; Rights Issue total receipts stood at ₹309.79 crores as of March 31, 2026. Ninth AGM scheduled for September 18, 2026 via VC/OAVM; no dividend declared for FY2025-26.